Interferons as potential adjuvants in prophylactic vaccines (Q37788270)

23 August 2017

Interferons as potential adjuvants in prophylactic vaccines (English)

1 reference

23 August 2017

1 reference

3

David B Weiner

1 reference

23 August 2017

Roberta Toporovski

1

1 reference

PubMed ID

20836750

23 August 2017

Matthew P Morrow

series ordinal

2

1 reference

PubMed ID

20836750

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

10

1 reference

23 August 2017

1489-1500

1 reference

Virus interference. I. The interferon

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Recognition of viruses by cytoplasmic sensors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

A species of human alpha interferon that lacks the ability to boost human natural killer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferons and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferon inhibits the conversion of 3T3-L1 mouse fibroblasts into adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Signaling pathways activated by interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferons: mechanisms of action and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

The IFN gamma receptor: a paradigm for cytokine receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferon-gamma: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

IL-28 and IL-29: newcomers to the interferon family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Biological activity of interleukins-28 and -29: comparison with type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

The antitumor effects of interferon: a personal history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Significant antitumor activity of oncolytic adenovirus expressing human interferon-beta for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Experimental autoimmune encephalomyelitis in Lewis rats: IFN-beta acts as a tolerogenic adjuvant for induction of neuroantigen-dependent tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

The effect of interferon-gamma on genetic immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Cytokines and costimulatory molecules as genetic adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Protection of chicken against very virulent IBDV provided by in ovo priming with DNA vaccine and boosting with killed vaccine and the adjuvant effects of plasmid-encoded chicken interleukin-2 and interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

An interferon gamma-gp120 fusion delivered as a DNA vaccine induces enhanced priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Augmentation of antigen-specific cytokine responses in the early phase of vaccination with a live-attenuated simian/human immunodeficiency chimeric virus expressing IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.521495

10.1517/14712598.2010.521495

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20836750